Search Results

You are looking at 1 - 10 of 7,188 items for :

Clear All
Free access

Jennifer Moliterno, William P. Cope, Emma D. Vartanian, Anne S. Reiner, Roselyn Kellen, Shahiba Q. Ogilvie, Jason T. Huse and Philip H. Gutin

A lthough meningiomas are the most common primary brain tumor, the anaplastic variant is exceedingly rare, accounting for 1%–3% of all meningiomas. 16 These tumors display frankly anaplastic histology with an undeniably malignant clinical course. Median overall survival (OS) has been reported as 1.5 years, 28 with 5-year survival ranging from 47% to 61%. 6 , 11 , 30 , 32 Given the rarity of this meningioma variant and scarcity of literature, relatively little is understood with regards to the underlying pathogenesis and factors that impact clinical

Restricted access

Kaisorn L. Chaichana, Patricia Zadnik, Jon D. Weingart, Alessandro Olivi, Gary L. Gallia, Jaishri Blakeley, Michael Lim, Henry Brem and Alfredo Quiñones-Hinojosa

G lioblastoma is the most common malignant primary CNS tumors in adults. 11 , 17 Despite advances in medical and surgical therapy, the median survival for patients harboring these tumors remains approximately 1 year. 11 , 13 These tumors frequently invade and infiltrate surrounding normal parenchyma, making curative resection unlikely. In fact, Walter Dandy performed hemispherectomies for glioblastoma in the 1920s, 10 and the tumors still recurred on the contralateral side. Despite extensive resection, these tumors will also continue to recur despite

Restricted access

Thomas Mindermann

A n increasing number of patients with brain metastases are undergoing GKS. Excellent local tumor control rates are achieved even in so-called radioresistant tumors such as metastases of RCC or malignant melanoma. 2, 3 To evaluate prognostic factors for tumor recurrence and patient survival following GKS for brain metastases, we reviewed our 7-year experience. Clinical Material and Methods Due to reimbursement policy in Switzerland, the vast majority of patients undergoing GKS for brain metastasis had a Karnofsky Performance Scale score greater than or

Restricted access

Benjamin C. Warf, Ernest J. Wright III and Abhaya V. Kulkarni

L ong-term survival of infants treated for MM and hydrocephalus in Sub-Saharan Africa is unknown. The CCHU has treated these infants over the past decade by closing the MM defect, treating hydrocephalus as needed, and providing management of neurogenic bladder. Furthermore, to avoid long-term shunt dependence and possible death due to shunt malfunction, we have successfully treated hydrocephalus by combined ETV/CPC in this population. 24 , 26 The objective of the present study was to evaluate long-term survival and its important determinants among patients

Restricted access

Fred G. Barker II, Michael D. Prados, Susan M. Chang, Philip H. Gutin, Kathleen R. Lamborn, David A. Larson, Mary K. Malec, Michael W. McDermott, Penny K. Sneed, William M. Wara and Charles B. Wilson

C ure of patients with glioblastoma multiforme (GBM) remains rare, even after treatment consisting of intensive multimodality therapy. Despite this uniformly lethal course, the survival of individual patients with GBM varies considerably. Some patients die of tumor progression before completing a 6-week course of radiation treatment, whereas others survive for 5 years or longer after diagnosis. 9 Although prognostic factors, such as age and Karnofsky performance scale (KPS) score, which help to predict the outcome of individual patients have been established

Restricted access

Goro Otsuka, Kiyoshi Saito, Tetsuya Nagatani and Jun Yoshida

patients with this disorder therefore poses difficult clinical problems, and planning requires consideration of patient survival rates as well as prognostically important clinical features. In our study, we analyzed data obtained in 74 patients with bilateral vestibular schwannomas and investigated both long-term survival in those who had NF2 and factors likely to influence it. Clinical Material and Methods Between 1986 and 1987, a nationwide questionnaire study was organized by the Ministry of Health and Welfare of Japan to clarify the clinicopathological

Restricted access

Matthew J. McGirt, Kaisorn L. Chaichana, Muraya Gathinji, Frank J. Attenello, Khoi Than, Alessandro Olivi, Jon D. Weingart, Henry Brem and Alf redo Quiñones-Hinojosa

M alignant astrocytomas, which include AAs (WHO Grade III) and GBMs (WHO Grade IV), are the most common malignant primary central nervous system tumors in adults. 10 Despite advances in medical and surgical therapy, the median survival remains < 2 years. 4 , 8 , 10 Although mean survival for patients with GBMs remains short, individual patient survival is heterogeneous. 36 As a result, there has been an emphasis on studying factors that are prognostic of improved survival in patients with malignant astrocytomas. 19 For many solid organ malignant

Restricted access

C. P. Yu, Joel Y. C. Cheung, Josie F. K. Chan, Samuel C. L. Leung and Robert T. K. Ho

S urvival of patients with brain metastases has traditionally meant a dismal prognosis; 9 however, authors of several studies have reported a more prolonged survival (≤ 2 years) in a subgroup of patients. 5, 12 Gamma knife surgery is now an established treatment modality for brain metastases. In this study, we aim as far as possible to analyze the characteristics of the patients, tumors, and treatment parameters associated with prolonged survival in patients with brain metastases. Clinical Material and Methods There were no predetermined patient

Restricted access

Predictors of survival in patients with prostate cancer and spinal metastasis

Presented at the 2009 Joint Spine Section Meeting 

Dan Michael Drzymalski, William K. Oh, Lillian Werner, Meredith M. Regan, Philip Kantoff and Sagun Tuli

P rostate cancer is the second leading cause of death from malignancy in men. 8 Although most people are cured of prostate cancer with surgery or radiation, most patients with recurrent prostate cancer develop metastatic disease during their lifetime, with the spine being the most common site of metastases. 5 , 18 The decision to use surgery to treat patients with spinal metastases and cord compression is a complex one that must take into account the patient's functional status as well as their expected survival. Considerable variability between patients

Restricted access

Douglas Kondziolka, Phillip V. Parry, L. Dade Lunsford, Hideyuki Kano, John C. Flickinger, Susan Rakfal, Yoshio Arai, Jay S. Loeffler, Stephen Rush, Jonathan P. S. Knisely, Jason Sheehan, William Friedman, Ahmad A. Tarhini, Lanie Francis, Frank Lieberman, Manmeet S. Ahluwalia, Mark E. Linskey, Michael McDermott, Paul Sperduto and Roger Stupp

P atients and their doctors both seek a reliable prediction of survival when a diagnosis of cancer is made. The most universal question is, “How long do you think the patient will live?” 22 Survival expectations are a frequent topic in doctor-patient discussions and doctor-doctor interactions. Thus, the reliability and accuracy of clinical and imaging data on individual patients outcomes is an important topic for study. 6–9 , 11 , 12 , 14 , 15 , 21 , 23 , 28 , 29 The majority of reports that detail clinical outcomes in patients with primary or metastatic